ORBIMED ADVISORS LLC 13D and 13G filings for ARS Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-11-30 4:23 pm Sale | 2022-11-08 | 13D | ARS Pharmaceuticals, Inc. SPRY | ORBIMED ADVISORS LLC | 7,788,510 8.300% | -1 (-0.00%) | Filing |
| 2020-12-11 4:47 pm Purchase | 2020-12-03 | 13D | ARS Pharmaceuticals, Inc. SPRY | ORBIMED ADVISORS LLC | 7,788,511 22.400% | 7,788,511 (New Position) | Filing |